The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies.

Choi H, Madari S, Daalman E, English BA, Halabi A, Hohl K, Shatillo Y, Weidinger N, Desch M

Open source

DOI
10.1007/s40268-026-00537-w
Published
2026 Mar
Container
Drugs in R&D
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40268-026-00537-w,
  title = {The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies.},
  author = {Choi H and Madari S and Daalman E and English BA and Halabi A and Hohl K and Shatillo Y and Weidinger N and Desch M},
  year = {2026},
  journal = {Drugs in R\&D},
  doi = {10.1007/s40268-026-00537-w},
  url = {https://doi.org/10.1007/s40268-026-00537-w}
}

RIS

TY  - JOUR
TI  - The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies.
AU  - Choi H
AU  - Madari S
AU  - Daalman E
AU  - English BA
AU  - Halabi A
AU  - Hohl K
AU  - Shatillo Y
AU  - Weidinger N
AU  - Desch M
PY  - 2026
JO  - Drugs in R&D
DO  - 10.1007/s40268-026-00537-w
UR  - https://doi.org/10.1007/s40268-026-00537-w
ER  - 

APA

H, C., S, M., E, D., BA, E., A, H., K, H., Y, S., N, W., & M, D. (2026). The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies.. Drugs in R&D. https://doi.org/10.1007/s40268-026-00537-w

Source records